Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression

Linlang Guo1, Yongguang Liu, Yifeng Bai

  • 1Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. linlangg@yahoo.com

European Journal of Cancer (Oxford, England : 1990)
|April 8, 2010
PubMed

Insights

MicroRNAs (miRNAs) play a key role in drug resistance in small cell lung cancer (SCLC). Researchers identified specific miRNAs, like miR-134, that can alter chemotherapy sensitivity and serve as potential biomarkers for SCLC treatment.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are crucial regulators of gene expression, influencing cell proliferation, apoptosis, and potentially drug sensitivity.
  • Understanding the role of miRNAs in multidrug resistance is vital for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) in multidrug resistance in small cell lung cancer (SCLC).
  • To identify novel molecular markers and therapeutic targets for overcoming chemotherapy resistance in SCLC.

Main Methods:

  • Utilized miRNA and cDNA microarrays to analyze the expression of 856 miRNAs and ~22,000 genes in sensitive (NCI-H69) and resistant (NCI-H69AR) SCLC cell lines.
  • Performed correlation analysis between miRNA and mRNA expression patterns.
  • Investigated the functional impact of specific miRNA mimics and antagomirs on drug sensitivity and cellular processes.

Main Results:

  • Identified 61 significantly differentially expressed miRNAs, with 48 novel associations with drug resistance.
  • Demonstrated that manipulating miR-134, miR-379, and miR-495 levels altered sensitivity to Cisplatin, Etoposide, and Doxorubicin.
  • Found that miR-134 promotes cell survival by inducing G1 arrest and negatively regulates MRP1/ABCC1, a key drug resistance factor.

Conclusions:

  • MicroRNAs play a substantial role in multidrug resistance in SCLC.
  • miR-134 is implicated as a causal factor in MRP1/ABCC1 down-regulation, contributing to drug resistance.
  • These findings highlight the potential of miRNAs as diagnostic biomarkers and therapeutic targets for SCLC drug resistance.